Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.-S.
Right arrow Articles by Kruh, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.-S.
Right arrow Articles by Kruh, G. D.
[Cancer Research 63, 4048-4054, July 15, 2003]
© 2003 American Association for Cancer Research

Experimental Therapeutics

Transport of Methotrexate, Methotrexate Polyglutamates, and 17ß-Estradiol 17-(ß-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport1

Zhe-Sheng Chen, Robert W. Robey, Martin G. Belinsky, Irina Shchaveleva, Xiao-Qin Ren, Yoshikazu Sugimoto, Douglas D. Ross, Susan E. Bates and Gary D. Kruh2

Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [Z-S. C., M. G. B., I. S., G. D. K.]; The National Cancer Institute, Bethesda, Maryland 20892 [R. W. R., S. E. B.]; The Institute for Cancer Research, Faculty of Medicine, Kagoshima University 890-8520, Kagoshima, Japan [X-Q. R.]; The Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 170-8455, Japan [Y. S.]; The Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine and The Baltimore Veterans Affairs Medical Center, Baltimore, Maryland 21201 [D. D. R.]

ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol. The antimetabolite methotrexate (MTX) was inferred recently to be an additional substrate of the pump based on the analysis of ABCG2-overexpressing cell lines. However, the transport characteristics of the pump with regard to this agent have not been determined. In addition, physiological substrates of ABCG2 have not been identified. Here we examine the in vitro transport properties of the pump using membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector. In so doing it is shown that MTX is a high capacity low affinity substrate of the pump, with Km and Vmax values of 1.34 ± 0.18 mM and 687 ± 87 pmol/mg/min, respectively. Unlike previously characterized multidrug resistance protein family members, ABCG2 is also able to transport MTX diglutamate and MTX triglutamate. However, addition of even one more glutamyl residue is sufficient to completely abrogate ABCG2-mediated transport. By contrast with the wild-type protein (ABCG2-R482), two ABCG2 variants that have been identified in drug selected cell lines, R482T and R482G, were unable to transport MTX to any extent. Similarly, folic acid was subject to efflux by the wild-type protein but not by the two mutants. However, transport of the reduced folate leucovorin was not detected for either the wild-type or the mutant proteins. Finally, it is shown that ABCG2 is capable of transporting E217ßG with Km and Vmax values of 44.2 ± 4.3 µM and 103 ± 17 pmol/mg/min, respectively. These results indicate that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members. In addition, it is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama
Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3)
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-l. Dai, A. K. Tiwari, C.-P. Wu, X.-d. Su, S.-R. Wang, D.-g. Liu, C. R. Ashby Jr., Y. Huang, R. W. Robey, Y.-j. Liang, et al.
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
Cancer Res., October 1, 2008; 68(19): 7905 - 7914.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Brand, P. A. I. van der Wel, M. J. Rein, D. Barron, G. Williamson, P. J. van Bladeren, and I. M. C. M. Rietjens
Metabolism and Transport of the Citrus Flavonoid Hesperetin in Caco-2 Cell Monolayers
Drug Metab. Dispos., September 1, 2008; 36(9): 1794 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. de Wolf, R. Jansen, H. Yamaguchi, M. de Haas, K. van de Wetering, J. Wijnholds, J. Beijnen, and P. Borst
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Mol. Cancer Ther., September 1, 2008; 7(9): 3092 - 3102.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS
J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. E. Eyler and J. N. Rich
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
J. Clin. Oncol., June 10, 2008; 26(17): 2839 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. Inoue, Y. Nakai, S. Ueda, S. Kamigaso, K.-y. Ohta, M. Hatakeyama, Y. Hayashi, M. Otagiri, and H. Yuasa
Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model
Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G660 - G668.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Velamakanni, T. Janvilisri, S. Shahi, and H. W. van Veen
A Functional Steroid-Binding Element in an ATP-Binding Cassette Multidrug Transporter
Mol. Pharmacol., January 1, 2008; 73(1): 12 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter
Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Shi, X.-X. Peng, I.-W. Kim, S. Shukla, Q.-S. Si, R. W. Robey, S. E. Bates, T. Shen, C. R. Ashby Jr., L.-W. Fu, et al.
Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2 Mediated Drug Resistance
Cancer Res., November 15, 2007; 67(22): 11012 - 11020.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Grube, S. Reuther, H. Meyer zu Schwabedissen, K. Kock, K. Draber, C. A. Ritter, C. Fusch, G. Jedlitschky, and H. K. Kroemer
Organic Anion Transporting Polypeptide 2B1 and Breast Cancer Resistance Protein Interact in the Transepithelial Transport of Steroid Sulfates in Human Placenta
Drug Metab. Dispos., January 1, 2007; 35(1): 30 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Oguri, Y. Bessho, H. Achiwa, H. Ozasa, K. Maeno, H. Maeda, S. Sato, and R. Ueda
MRP8/ABCC11 directly confers resistance to 5-fluorouracil
Mol. Cancer Ther., January 1, 2007; 6(1): 122 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M. A. J. van Eijndhoven, C. J. F. de Wolf, A. Kuil, J. H. Beijnen, G. L. Scheffer, G. Jansen, et al.
The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models
Mol. Pharmacol., January 1, 2007; 71(1): 240 - 249.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Jungsuwadee, M. P. Cole, R. Sultana, G. Joshi, J. Tangpong, D. A. Butterfield, D. K. St. Clair, and M. Vore
Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice.
Mol. Cancer Ther., November 1, 2006; 5(11): 2851 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev, October 1, 2006; 86(4): 1179 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Seamon, C. A. Rugg, S. Emanuel, A. M. Calcagno, S. V. Ambudkar, S. A. Middleton, J. Butler, V. Borowski, and L. M. Greenberger
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
Mol. Cancer Ther., October 1, 2006; 5(10): 2459 - 2467.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
S. Vander Borght, L. Libbrecht, A. Katoonizadeh, J. van Pelt, D. Cassiman, F. Nevens, A. Van Lommel, B. E. Petersen, J. Fevery, P. L. Jansen, et al.
Breast Cancer Resistance Protein (BCRP/ABCG2) Is Expressed by Progenitor Cells/Reactive Ductules and Hepatocytes and Its Expression Pattern Is Influenced by Disease Etiology and Species Type: Possible Functional Consequences
J. Histochem. Cytochem., September 1, 2006; 54(9): 1051 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
S. Choudhuri and C. D. Klaassen
Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters
International Journal of Toxicology, July 1, 2006; 25(4): 231 - 259.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, et al.
A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
C. J. Henrich, H. R. Bokesch, M. Dean, S. E. Bates, R. W. Robey, E. I. Goncharova, J. A. Wilson, and J. B. McMahon
A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
J Biomol Screen, March 1, 2006; 11(2): 176 - 183.
[Abstract] [PDF]

Home page
 J AndrolHome page
R. Obligacion, M. Murray, and I. Ramzan
Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition
J Androl, March 1, 2006; 27(2): 138 - 150.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Shafran, I. Ifergan, E. Bram, G. Jansen, I. Kathmann, G. J. Peters, R. W. Robey, S. E. Bates, and Y. G. Assaraf
ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates
Cancer Res., September 15, 2005; 65(18): 8414 - 8422.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Matsushima, K. Maeda, C. Kondo, M. Hirano, M. Sasaki, H. Suzuki, and Y. Sugiyama
Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1059 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. J. Huss, D. R. Gray, N. M. Greenberg, J. L. Mohler, and G. J. Smith
Breast Cancer Resistance Protein-Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem Cells
Cancer Res., August 1, 2005; 65(15): 6640 - 6650.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
Cancer Res., August 1, 2005; 65(15): 6943 - 6949.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. L. A. Sesink, I. C. W. Arts, V. C. J. de Boer, P. Breedveld, J. H. M. Schellens, P. C. H. Hollman, and F. G. M. Russel
Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides
Mol. Pharmacol., June 1, 2005; 67(6): 1999 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al.
The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates
Cancer Res., May 15, 2005; 65(10): 4425 - 4430.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Q. Xia, N. Liu, D. Yang, G. Miwa, and L.-S. Gan
EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS
Drug Metab. Dispos., May 1, 2005; 33(5): 637 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
U. Henriksen, U. Gether, and T. Litman
Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2
J. Cell Sci., April 1, 2005; 118(7): 1417 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
Cytoplasmic Confinement of Breast Cancer Resistance Protein (BCRP/ABCG2) as a Novel Mechanism of Adaptation to Short-Term Folate Deprivation
Mol. Pharmacol., April 1, 2005; 67(4): 1349 - 1359.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. F. K. Ejendal and C. A. Hrycyna
Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A
Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Spees, T. P.F. Gade, G. Yang, W. P. Tong, W. G. Bornmann, R. Gorlick, and J. A. Koutcher
An 19F Magnetic Resonance-Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle
Clin. Cancer Res., February 15, 2005; 11(4): 1454 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z.-S. Chen, Y. Guo, M. G. Belinsky, E. Kotova, and G. D. Kruh
Transport of Bile Acids, Sulfated Steroids, Estradiol 17-{beta}-D-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11)
Mol. Pharmacol., February 1, 2005; 67(2): 545 - 557.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Burger, H. van Tol, A. W. M. Boersma, M. Brok, E. A. C. Wiemer, G. Stoter, and K. Nooter
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
Blood, November 1, 2004; 104(9): 2940 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions
Cancer Res., August 15, 2004; 64(16): 5804 - 5811.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Gupta, Y. Zhang, J. D. Unadkat, and Q. Mao
HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 334 - 341.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS
J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.-M. Scherrmann
Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier
Cancer Res., May 1, 2004; 64(9): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. L. R. Ee, S. Kamalakaran, D. Tonetti, X. He, D. D. Ross, and W. T. Beck
Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene
Cancer Res., February 15, 2004; 64(4): 1247 - 1251.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.